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 Omega-3 (n-3) and omega-6 (n-6) fatty acids have been known to be essential for normal 
growth and dermal functions since the 1930s, and multiple benefits of n-3 fatty acids have been 
recognized over the last 20 years. α-linoleic acid (ALA), an omega-3 fatty acid, is of particular 
interest because of its suspected role in up-regulating global fatty acid oxidation in adipocytes 
and skeletal muscle cells. ALA is a substrate for β-oxidation in humans, and also can be 
elongated to longer-chain polyunsaturated fatty acids (PUFAs) in the endoplasmic reticulum via 
interactions with desaturase and elongase enzymes. Under long-chain PUFAs deficient 
conditions, ALA would be converted, but under normal conditions the ALA is competitively 
inhibited from interacting with ∆6-Desaturase enzyme. N-3 and n-6 fatty acids are metabolized 
by the same desaturation/elongations pathway; therefore, there exists the potential for 
competitive inhibition when there are sufficient intracellular concentrations of both families of 
fatty acids. The logical question that arises is: what happens to the ALA not allowed to 
participate in the desaturase/elongation pathway? Clearly, it is going to be metabolized, but what 
mechanisms are involved in this process and are they ALA-specific? The hypothesis is that the 
mechanisms are not ALA-specific; therefore, the metabolism of surplus ALA will affect the 
metabolism of other fatty acids. To determine if surplus ALA regulates global fatty oxidation, 
experiments were ran using the C2C12 cell line of mouse adipocytes. After cells were grown, 
differentiated, and labeled with 
3
H-palmitate, 15 different treatments containing various 
concentrations of ALA, arachidonic acid (ARA), eicosapentaenoic acid (EPA), and 
docosahexenoic acid (DHA) were added in vitro. The treatments that contained all four n-3 fatty 
acids mimicked in vivo conditions (25µM ARA, 25µM 3:2 EPA:DHA) . Initial experiments 
show a 141%, 41%, 195%, and 97% increase in fat oxidation in response to progressive 
increases in ALA from 0 to 10, 25, 50, and 100µM ALA, respectively. These data show that 
ALA does affect the oxidation of other fatty acids, although, the subsequent experiment did not 
replicate the initial’s results. Therefore, more experiments need to be run to address the lack of 
fatty acid oxidation dose-responsiveness. If in fact the initial experiment’s observations hold 
true, some hypothesized mechanisms that might cause up-regulated of fatty acid oxidation are 
increased activity of Carnitine Palmitoyl Transferase I (CPT-I), the ligand-activated 
transcriptional factors peroxisomal proliferator activated receptor-α (PPARα) and PPARδ, and 
such downstream effects as increased mitochondrial biogenesis. 
 
Introduction: 
 Obesity has become an obvious killer in not only America, but throughout the world. A 
combination of work-related stress, sedentary lifestyle, and poor nutrition has created and 
allowed the prevalence of obesity to more than double since 1980
1
. Now, 65% of the world’s 
population lives in countries where obesity-related deaths have overtaken non-obesity-related 
deaths
1
. Luckily, obesity is a preventable condition, and as the prevalence of obesity continues to 
grow throughout the world, there is increasing interest in a possible solution amongst the 




 This project evaluates the effect of a specific omega-3 (n-3) polyunsaturated fatty acid 
(PUFA), but a more general perspective on the history of n-3 PUFA research is necessary to 
understand the reasoning which led to this study’s focus. 
 Numerous studies have used diet-induced and genetically obese mice to study the effects 
of n-3 PUFA on mice, effects such as: weight loss, fat reduction, and protective benefits against 
the accumulation of body fat
2
. The diets among certain studies varied. Usually, the mice were 
categorized into two groups, two high-fat diets with the second group being supplemented with 
fish oil or EPA/DHA, a high-fat supplemented diet and low-fat/control diets, or a multiple high-
fat diets supplemented with different absolute amounts of EPA/DHA or fish oil
3
. 
 Multiple studies have supported the claim that long chain n-3 PUFA have protective 
effects regarding body fat accumulation. Hainault et al. found that, although body weight did not 
change, Wistar rats that consumed a lard-fish oil diet (33% lard, 20% casein, 30% starch, 2% 
corn oil, 15% fish oil) had 20% less inguinal adipose tissue and 30% retroperitoneal and 
epididymal adipose tissue after the 20-day study
4
. Parrish et al. found through a high-fat (20% 
triglycerides from fish oil or 20% from lard oil) diet study, his Wistar rats in the fish oil group 
did not differ in body weight from the lard oil group, but Parrish saw a significant reduction in 
peririenal and epididymal fat from the lard oil group
2
. Several more studies delved further into 
the correlation between n-3 PUFA supplementation and fat reduction, specifically discovering a 
dose-dependent relationship
5
 and suggestion that DHA is primarily responsible for encouraging 
reduction of cellularity and attenuation of visceral fat accumulation
6
.  
 The accumulating evidence for the beneficial effects of long chain n-3 PUFA is exciting. 
Though, for the sake of fair argument, one 2006 study did offer contradicting evidence. Todoric 





 diabetes mice on high-fat diets
7
. He found that those mice on a high-
fat diet (30% of energy) which were given a n-3 PUFA-rich supplement actually had significant 
weight gain compared with the mice on a n-6 PUFA-rich diet
7
. Although body fat was not a 
parameter measured in the Todoric et al. study, the findings do lend to the speculation that long 
chain n-3 PUFA have different metabolic impacts on mice with diabetes
3
. Contrastingly, the 
study also provides support for n-3 PUFA interference with white adipose tissue 
proinflammatory response of mice on obese mice
7




 α-linolenic acid (18:3n-3, ALA) is an essential n-3 PUFA in the human diet and is the 
principal fatty acid in the western diet
8
. ALA is converted to longer-chain PUFA in the 
endoplasmic reticulum of the liver
10
 of human adults, and is of particular interest since the 
conversion pathway yields the PUFA eicosapentaenoic acid (EPA) (20:5n-3) and 
docosapentaenoic acid (DHA) (22:6n-3). Figure 1 provides a general pathway for ALA 
conversion to longer n-3 PUFA. Studies have not yet shown if the ∆6-Desaturase enzymes that 
participate in the conversion pathway are the same enzyme or two distinct ones. Also, both n-3 
and n-6 PUFA are metabolized by the same desaturation/elongation pathway, so, therefore, there 
exists the potential for competitive competition between n-3 and n-6 PUFA
8
. In fact, ∆6-
Desaturase has a greater affinity for ALA although linoleic acid is at greater cellular 
concentration than ALA, causing greater conversion of the n-6 PUFA. The effect of increased 
consumption of ALA is of interest because of the supposed increase of n-3 PUFA conversion if 
ALA intracellular stores were to be increased. Also, the effect of sufficient amounts of 
intracellular EPA/DHA, specifically DHA since it has been found to be the primary parameter 
affecting visceral fat accumulation
6
, is of interest since competition for ∆6-Desaturase within the 
pathway would lead to feedback inhibition. In fact, the conclusion of a 1994 
13
C- isotope 
incorporation study stated that the conversion of ALA, which entered the desaturase/elongase 
pathway, to DHA is 4%
9
; while a 2002 study of young men found no detectable radioactive 
DHA up to 21 days
10
. Tang et al. found that n-3 and n-6 PUFA suppressed  
 
Figure 1: General pathway for ALA conversion through multiple desaturase and elongase steps (based on 
reference 8).  The initial reaction is the rate-limiting step. 24:6n-3 is translocation from the ER to the 
peroxisome where the acyl chain is shortened. 22:6n-3 (DHA) is translocated back to the ER
8
. 
hepatic expression of rodent ∆6-Desaturase by inhibiting its gene transcription
11
. Specifically, 
∆6-Desaturase contains a response element for the ligand-activated transcription factor 
peroxisomal proliferator activated receptor-α (PPARα) in its promoter region, and DHA was 
found to bind to PPARα thus promoting the previously mentioned inhibition of ∆6-Desaturase 
gene transcription
8, 11
. The studies lead to the conclusion that feedback inhibition of the 
desaturase/elongase pathway by DHA would result in even lower conversion of ALA to EPA 
and DHA.  
 With this knowledge about the feedback inhibition of ALA conversion pathway, a logical 
question would be: what happens to the ALA if it does not participate in the conversion to longer 
chain n-3 PUFA? We suspect that the excess ALA plays a role in up-regulation of global fatty 
acid oxidation in adipocytes and skeletal muscle cells. The excess ALA is most likely 
metabolized, but since an ALA-specific oxidation mechanism has not yet been discovered, nor is 
one postulated to exist, the increase in ALA oxidation would increase other fatty acid 
metabolisms as well.  
 
Materials/Methods: 
 To determine if surplus ALA regulates global fatty oxidation, experiments were ran using 
the C2C12 cell line of mouse adipocytes.  
 
Initial Preparation: 
 Initial C2C12 mouse adipose tissue line was withdrawn from liquid nitrogen and thawed. 
The thawed C2C12 cells were then introduced into a 75cm
2
 canted neck flask (T75) from Fisher 
Scientific™ . The thawed cells were fed with phenol red Dulbecco’s Modified Eagle Medium 
(DMEM) high glucose1X (GIBCO®). Penicillin-streptomycin (pen-strep), an antibiotic, and 
Fetal Bovine Serum (FBS), a serum-supplement with low level of antibodies and high level of 
growth factors,  were added at 1% and 10% solution composition, respectively, in order to 
diminish risk of contamination and encourage cell growth. The cells were always kept in a 37
o
C 
incubator when not examined or re-fed. The DMEM/10%FBS/1%pen-strep (growth medium) 
was changed everyday until the cells became 80-90% confluent. When cells were 80-90% 
confluent, they were washed with Hank’s Balanced Salt Solution (HBSS) 3 times, then washed 
with trypsin-EDTA 1X (Mediatech™), spun down in 50mL falcon tube to remove supernatant, 
and then the pellet of cells were re-suspended in 210mL of the growth medium. Then, the 
dilution was split amongst 8x24 well-plates, with 1mL of solution into each well for a total of 
192 wells. The growth medium was changed everyday. When the cells in the well-plates became 
80-90% confluent, a new DMEM/2%Horse Serum/1%pen-strep (differentiation medium) was 
mixed to promote cell differentiation. After 3 days of differentiation medium supplementation, a 
new medium serum-free mixture was created containing DMEM/0.2%Horse Serum/1%pen-
strep. The cells were allowed to incubate for 24 hours in the serum-free mixture before they were 
ready for the fatty acids treatments. 
 
Treatments: 
 Fifteen different treatments were used. The main fatty acids used were arachidonic acid 
(ARA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DHA) and α-linlenic acid (ALA). 
There were 3 main groups, each with the same 5 ALA concentrations, yielding a total of 15 
treatments. The 3 main treatment groups were: the control (solvent), 25µM ARA, and 25µM 3:2 
EPA:DHA. Each group had the same 5 ALA concentrations mixed into the solution: 0, 10, 25, 
50, and 100µM ALA. The solvent for the treatments was DMEM + Bovine Serum Albumin, 
which acts as a transport protein for the fatty acids into the cells.  
30X ALA, ARA, and EPA:DHA concentrations were made up from the ethanol dissolved 
pure fatty acids. These 30X concentrations were then diluted into the final concentrations by the 
solvent. The solvent composed of 495mg of BSA for every 15mL of DMEM needed. To have 
sufficient fatty acid treatments, 15mL of each of the 15 treatments were made up and 1mL of the 
appropriate treatment was added to the 12 corresponding wells. The treatments were incubated at 
37
o
C/5%CO2 for 12-16 hours.   
 
Fatty Acid Oxidation Protocol: 
 Reaction Mixture: There The 12 wells per treatment were split into 6 positive, 
tritium(5µCi)-labeled protein wells and 6 negative, formalin(10% Phosphate Buffered Solution)-
labeled wells. The 6 negative wells were labeled with formalin in order to kill the cells and 
ensure there would be no activity except background counts recorded. This provides high count 
contrast in relation to the tritium-labeled wells and ensures the recorded radioactive was not just 
background radioactivity. The reaction mixture added to each well composed of 20mL HBSS, 10 
mg BSA, 200µl unlabeled palmitate, and 531µl tritium for the positive controls. For the negative 
controls, 531µl of formalin was added, replacing the tritium. 
 Addition/Incubation: Once the reaction mixture was made, each well received 200 µl of 
the appropriate mixture. Any wells that exhibited contamination from the previous ALA 
treatments were skipped. After the addition of the appropriate mixtures, the well plates were 
incubated at 37
o
C/5% CO2 for 2 hours.  
 Protocol Preparation: Chromatography columns with resin solution were prepared the 
night before the protocol was run. A total of 180 columns were sorted onto racks, and 2. mL of 
resin solution was added to each column. The resin solution composed of 20 g of Dowex ® 1X2, 
200-400 mesh, ion-exchange resin (Acros Organics®) for every 55mL of MilliPore® filtered 
water. A large beaker was used to contain sufficient resin solution for the 180 columns, and the 
solution was constantly stirred via magnet stirring rod until all columns had 2.5mL resin 
solution. They were allowed to sit overnight. Also, the night before and/or during the 2 hour 
incubation, 2 sets of 180 2mL vials were labeled 1-180 and ordered onto racks for use later in the 
protocol. Also, 200µl of trichloroacetic acid (TCA) was added to each tube during the 2 hour 
incubation period. The TCA should be 10% wt/vol. 
 Protocol Procedure: After the 2 hour incubation period, all 8 well-plates were taken out 
of the incubator. The mixture from each well was removed and placed into itself appropriately 
labeled 2mL vial. When the entire well is finished, 100µl of Phosphate Buffered Saline (PBS) 
was added to each well. After 1 minute, the PBS was removed and added to its appropriately 
labeled vial. After the vials sat for 2 minutes, they were centrifuged at 8,500g for 5 minutes. At 
this time, the twist-off caps at the bottom of the chromatography columns were broken, allowing 
the water to sift through the now-settled resin. After the 5 minute centrifuge wait, the supernatant 
was removed immediately and placed into the 2
nd
 set of appropriately labeled 2mL vials. A 70µl 
addition of 6N NaOH proceeded in order to counteract the TCA. The supernatant/NaOH mixture 
was then transferred to its appropriately labeled chromatography column. Each column then 
received 1mL of MilliPore® filtered water to facilitate the wash of the supernatant/NaOH 
mixture through the resin. The filtrate was collected in an empty scintillation vial and left 
overnight. The well-plates now only contained the cell layer, so 500µl of MilliPore® filtered 
water was added to each well. The well-plate was then taped shut and put into a -80
o
C freezer 
until ready for the protein correction protocol. The next day, 10mL of Bio-Safe II™ scintillation 
fluid was added to each scintillation vial. The vials were then put into a liquid scintillation 
counter which recorded the counts per minute (CPMs) at a 1 minute rate. The vials were then 
taken out and kept behind a radioactive-material protective hood.  
 
Protein Correction: 
 Once the CPMs for each well were recorded, a protein correction was run either using the 
Commassie Protein Assay Kit (Thermo Scientific ®) or the BCA protein assay reagent kit 
(Thermo Scientfic ®). A spectrophotometer assisted by a spectral count program was used to 
interpret the data into numerical form. Given this information, the corrected CPM/µg of protein 





 The initial experiment data, for the 3:2 25µM EPA:DHA treatments, show a 141%, 41%, 
195%, and 97% increase in fat oxidation in response to progressive increases in ALA from 0 to 
10, 25, 50, and 100µM ALA concentrations, respectively (Figure 2). Also, the 25µM ARA 
treatments show an initial decrease of 4.1%, but then a rebound of 31%, 266% before another 
loss in oxidation of 32% in response to progressive increases in ALA from 0 to 10, 25, 50, and 
100µM ALA, respectively (Figure 3). The initial data for both EPA:DHA and ARA treatments 
show increases in fat oxidation for palmitate (16:0). There was an observed 33% and 82% 
decrease in fat oxidation from 50 to 100µM ALA concentrations within the EPA:DHA and ARA 
treatments, respectively, suggesting a possible threshold for increasing oxidation at 50µM ALA 
for both treatments. 
 For the subsequent experiment, the EPA:DHA treatments showed decreases of 47%, 
30%, 36%, and 34% in fat oxidation from 0 to 10, 25, 50, and 100µM ALA concentrations, 
respectively. The ARA treatments showed initial increases of 54%, 27%, and then decreases of 
1.6% and 29%, respectively. 
 The initial experiment did suggest a ALA-stimulated increase in palmitate oxidation, but 
only one subsequent experiment was ran due to time constraints and its data did not replicate the 
initial experiment’s. Due to lack of consistent data, this study’s interpretation of whether ALA 
does up-regulate fatty acid oxidation will be left inconclusive until more repeat experiments are 
run. 
 
Sources of Error: 
 Similar to any scientific experiment, there are possible sources of error that should be 
enumerated in order to maintain scientific integrity.  
 Aside from any inherent human error, certain initial and subsequent ARA and EPA:DHA 
treatments did not have the full 6 positive and 6 negative controls as listed in the Fatty Acid 
Oxidation Protocol above. In the ARA initial treatments, 0 and 25µM ALA concentrations had 4 
and 5 positive controls, respectively. In the EPA:DHA initial treatments, 25µM ALA 
concentration had 5 positive controls. In the subsequent ARA experiment, 25µM 
ALA concentration had 5 positive controls. In the subsequent EPA:DHA experiment, 0µM ALA 
























Figure 2: Initial experiment changes in palmitate oxidation at various concentrations of ALA within the 
EPA:DHA treatments. The data suggests ALA-stimulated increase in fat oxidation and a possible threshold 
for oxidation around 50uM ALA. Error bars represent the standard error of the mean. 






















Figure 3: Initial experiment changes in palmitate oxidation at various concentrations of ALA within the ARA 
treatments. The data also suggests ALA-stimulated increase in fat oxidation and a possible threshold for 
oxidation around 50uM ALA. Error bars represent the standard error of the mean. 
 
 
concentration had 5 positive controls. One or two fewer positive, tritium-labeled controls 
increases the susceptibility of the mean to outliers in the data, therefore, leading to sample data 
that are not representative of the proposed cell population. A solution would be to run more 
repeat experiments in the future to obtain more sample data, therefore, making the complete 
sample data more representative of the proposed cell population. 
 Another possible source of error stems from the time dedicated to finishing the fatty acid 
oxidation protocol. With only one researcher working through the protocol, each plate took about 
45 minutes to complete meaning that the 8
th
 plate could have sat at room temperature for 6 hours 
before beginning the protocol after the 2 hour incubation period. This extra time, even though at 
room temperature, could have affected the recorded CPM of the latter treatment plates. A 
solution would be to have more than one researcher completing the protocol once started and/or 
investigating the effects of refrigerating the treatment plates until they are needed after the 2 hour 




 Multiple repeat experiments will have to be run to obtain consistent data before any of 
the following hypotheses will be tested.  
 
Mechanisms of Action: 
 If the repeat experiment suggest ALA dose-dependent up-regulation of fatty acid 
oxidation response, the next step would be to understand exactly how these increases in fatty 
acid oxidation are caused.  
 Carnitine palmitoyltransferase I (CPT1) is one of the cycle carnitine enzymes that 
transport long chain fatty acids from the cytoplasm into the mitochondria
12
 for incorporation into 
the β-oxidation pathway. Hypothesized mechanisms to investigate are the up-regulation of 
CPT1, and more specifically CPT1B, the muscle-type isoform of CPT1
12
, activity.   
 Also, there is significant interest in the role of PPARα and PPARδ, PPAR isoforms, in 
the regulation of fatty acid oxidation. Studies have found that the PPARs modulated enzymes 
involved in lipid metabolism, especially in metabolically active tissues such as sketetal and 




 Future studies will be run that will investigate these proposed mechanisms of action of 
fatty acid oxidation regulation. Also, repeat fatty acid oxidation protocol experiments will be ran 
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